GALECTIN 1 RESCUES MICROVASCULAR ALTERATIONS IN ALZHEIMER’S DISEASE IN IN VIVO AND IN VITRO MODELS INVOLVING ENDOPLASMIC RETICULUM STRESS PATHWAYS

PRESA, J.; POMILIO, C.; GORI, S.; MATZKIN, M.E.; ALAIMO, A.; SOIZA-RELLY, M.; PEREZ, O.; RAMHORST, R.; BEAUQUIS, J.; RABINOVICH, G.; SARAVIA, F.

Congreso; Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2023

As a multifactorial pathology, Alzheimer’s disease (AD) exhibits marked vascular alterations that correlate with disease progression. The immense impact of AD requires new and effective therapeutics. Galectins, a family of proteins that bind to outer membrane oligosaccharides, trigger various cell responses involving immune and vascular modulation. Galectin-1 (Gal1) may have beneficial effects on neurological disorders. We treated PDAPPJ20 (Tg) mice -an AD model- with Gal1(3 weekly i.p. injections of 100 ug/dose, 9 injections). Tg-Gal1 mice showed a 50% reduction in perivascular Aβ compared to vehicle-treated littermates (Tg-Veh) (p